estramustine

Estramustine is an antineoplastic agent used primarily for the palliative treatment of metastatic and/or progressive prostate cancer. It is a unique combination of an estrogen (estradiol) and a nitrogen mustard (mechlorethamine), designed to exploit both hormonal and cytotoxic mechanisms. The drug works by two main actions: the estrogen component lowers testosterone levels, which slows or stops the growth of hormone-dependent prostate cancer cells; meanwhile, the nitrogen mustard moiety acts as an alkylating agent that damages DNA in rapidly dividing cells, leading to cell death. Additionally, estramustine binds to tubulin and disrupts microtubule dynamics necessary for cell division[1][3][4][6][8]. Developed by Pharmacia and currently manufactured by Pfizer, estramustine is most commonly marketed under the brand name Emcyt. It is not typically used as first-line therapy but rather in cases where prostate cancer has progressed or metastasized despite other treatments. The drug’s dual mechanism—hormonal suppression via estrogenic activity and direct cytotoxicity via DNA alkylation—makes it distinct among therapies for advanced prostate cancer[1][3][4]. Estramustine also stabilizes microtubules by binding to tubulin at a site distinct from other agents like colchicine or vinblastine[6].

Brand names

Emcyt

Other names

estramustine phosphateestradiol nitrogen mustardestromustine